COMMUNIQUÉS West-GlobeNewswire

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
16/03/2026
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE [...]
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
16/03/2026
Companies Resolve Lawsuit in Delaware BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
16/03/2026
NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are [...]
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
16/03/2026
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 [...]
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
16/03/2026
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy in [...]
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
16/03/2026
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16, 2026 [...]
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
16/03/2026
Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), caused by [...]
SAFE - Modification de la composition du Conseil d'Administration
16/03/2026
Modification de la composition du Conseil d'Administration Fleurieux-sur-l’Arbresle - France - le 16 mars 2026 à 8h. SAFE Group annonce des évolutions significatives au sein de son Conseil d'Administration. Cooptation d [...]
EssilorLuxottica et Dolce&Gabbana renforcent leur partenariat jusqu’en 2050
16/03/2026
EssilorLuxottica et Dolce&Gabbana renforcent leur partenariat jusqu’en 2050 Paris, France et Milan, Italie (16 mars 2026) - EssilorLuxottica et Dolce&Gabbana annoncent l’extension de leur accord de licence jusqu [...]
OSE Immunotherapeutics annonce son calendrier financier pour 2026
16/03/2026
Nantes, France, 16 mars 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) annonce aujourd’hui son calendrier financier pour 2026. Information Date* Résultats financiers annuels 2025 29 [...]
EssilorLuxottica and Dolce&Gabbana further strengthen their partnership through 2050
16/03/2026
EssilorLuxottica and Dolce&Gabbana further strengthen their partnership through 2050 Paris, France and Milan, Italy (16 March 2026) - EssilorLuxottica and Dolce&Gabbana announced today the extension of the [...]
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
GN Store Nord A/S enters into agreement to sell its Hearing business to Amplifon S.p.A. for DKK 17.0 billion
16/03/2026
Today, GN Store Nord A/S (“GN”) has entered into a definitive agreement for the sale of GN’s Hearing business to Amplifon S.p.A. (“Amplifon”), a leading global hearing care retailer. The transaction values the Hearing [...]
OSE Immunotherapeutics Announces its 2026 Financial Calendar
16/03/2026
Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information Date* 2025 Full-Year Financial Update and Statements [...]
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
16/03/2026
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachments notification-of-managers-transaction [...]
Dvorak Botanicals Launches Low-Dose Hemp-Derived THC Gummies Focused on Mindful Consumption
16/03/2026
Atlanta, GA, March 16, 2026 (GLOBE NEWSWIRE) -- Dvorak Botanicals, a new premium hemp-derived THC brand founded by Atlanta-based entrepreneur Dane Dvorak, has launched with a focus on controlled-dose hemp products that [...]
Idorsia announces management change
16/03/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti will step down from [...]
Tecan presents 2025 results and provides details on program to reignite profitable growth
16/03/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan presents 2025 results and provides details on program to reignite profitable growth Financial results for the full year 2025 [...]

Pages